Postoperative infections after knee or hip joint replacements are among the most feared complications in orthopaedic surgery. At the EFORT Congress in London current research was presented that provides new insights in this field: Fracture patients are especially vulnerable to infection. New biomarkers should improve early diagnosis of risky infections.
Future of DNA sequencing will shift from a laboratory-based setup to point of care testing in the next 5 years
Reliable results can only be achieved in urine diagnostics, if correct preanalytical conditions are ensured. Urine collection, specimen transport and further storage are critical influential factors for sample quality and can affect the results.
About four years ago, Samsung Electronics Co. – specialist in electronic components and mobile phone sets, was recognised by its revenues as the world’s largest IT company, displacing Apple Inc.
A small prick to sample blood instead of complex pathological or other diagnostic procedures – this is how early cancer diagnosis will be in the near future. Blood tests to diagnose tumorous diseases early are already being researched for clinical use.
Despite a slight drop in sales in 2013 compared to the previous year, for 2014 the German medical diagnostics manufacturers anticipate a positive business development, according to the trend indicator presented by the business association Verband der Diagnostika-Industrie (VDGH) in Berlin.
Olympus launches its OlyVIA Mobile iPad App, an image viewer dedicated to virtual slides.
Offering attractive procurement strategies will boost adoption of high-end tools
GE and Thermo Fisher Scientific announced yesterday that they have entered into an agreement for GE Healthcare to acquire Thermo Fisher’s HyClone cell culture media and sera, and gene modulation and magnetic beads businesses for approximately $1.06 billion.
Down’s syndrome (also referred to as trisomy 21) is a genetic disorder caused by the presence of all or part of an extra copy of chromosome 21 in a person’s DNA. Current screening for Down’s syndrome and other trisomy conditions includes a combined test done between the 11th and 13th weeks of pregnancy.
The number of patients treated with implants – from cardiac pacemakers, heart valves and vascular implants to artificial hips and knees – is rising worldwide.
Over the past decade the use of point-of-care testing (POCT) in European and North American hospitals has steadily increased, stimulated by the objectives of accelerating diagnostic treatment, increasing efficiency and improving patient outcomes.
Today, Siemens Healthcare Diagnostics Inc. announces that it has entered into a master collaboration agreement with Pfizer Inc. to design, develop and commercialize diagnostic tests for therapeutic products across Pfizer’s pipeline.
Ahead of regulatory approval that is expected before the end of the year, Trinity Biotech chose Medica to present the novel point-of-care (POC) analyzer Meritas with the Troponin I (TnI) that are expected to disrupt a €700 million market.
Born in the USA out of the anthrax scare that followed the 9/11 attacks, the formation of a network of laboratories kept on 24/7 alert against potential bio-terrorism was introduced in France at the end of 2001.
Down’s syndrome (also referred to as trisomy 21) is a genetic disorder caused by the presence of all or part of an extra copy of chromosome 21 in a person’s DNA.
Using electrically conductive, ink-like materials, a Swedish consortium has created a fully functional prototype for a self-monitoring blood glucose (SMBG) test that could be disruptive for in vitro diagnostics.
Clinical chemistry influences almost all medical disciplines: most diagnoses are made or confirmed only after the laboratory has determined at least one or two parameters.
Internet-based training for clinicians could help lower antibiotic prescribing rates for acute respiratory tract infections by as much as 62%, according to British researchers.
In intensive care units (ICUs) little can be automated to relieve staff pressures – with the exception of point of care testing (POCT)
Nat Whitney, President of Whitney Research, sums up the ups and downs of the international IVD market and reports on a fitting finale for 17 years of dedicated service
Snibe, the Shenzhen New Industries Biomedical Engineering Company Ltd., is a leading Chinese biomedical technology company dedicated to developing and manufacturing clinical laboratory equipment and in vitro reagents. Founded 18 years ago and a growing force in the Chinese market, the firm is based in Shenzhen, China’s fourth largest city, situated in Guangdong Province.
The Allegra X-5 air-cooled benchtop centrifuge from Beckman Coulter Life Sciences is designed specifically for clinical sample preparation.
About 500,000 people in France people suffer heart failure (HF). In Europe the figure is six million and the same in the USA.
Which technological advancements can we expect to see in the field of medical technology? How well can diagnosis and therapy be customized for each patient?
